预约演示
更新于：2025-09-29
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2025-09-29
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
60
项与 头孢他啶阿维巴坦钠 相关的临床试验NCT06864585
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
NCT06811727
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)
NCT06939829
A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
412
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
KPC-157 and KPC-181 carbapenemases produced by Citrobacter freundii ST522 and Klebsiella pneumoniae ST258 isolated from wastewater
Article
作者: Barbosa, Mikaela Renata Funada ; Sousa-Carmo, Rubens Renato ; Lincopan, Nilton ; Power, Pablo ; Silva, Renan Lourenço Oliveira ; Brunetti, Florencia ; Sato, Maria Ines Zanoli ; Furlan, João Pedro Rueda ; Schenkman, Sergio ; Bueno, Giovanna Carrasco
BACKGROUND:
While novel KPC variants continue to emerge among clinically relevant Enterobacterales from hospital settings, their occurrence in impacted aquatic environments has been poorly investigated. We hereby report KPC-157 and KPC-181, allelic variants of KPC-2, produced by Citrobacter freundii and Klebsiella pneumoniae isolated from wastewater in Brazil.
METHODS:
Antimicrobial susceptibility was determined by disk diffusion and broth microdilution, whereas carbapenemase production was evaluated by inhibitor-based methods. Genome sequencing was performed combining short-read (Illumina HiSeq) and long-read (Oxford Nanopore) technologies, with further bioinformatic analyses. In silico KPC modeling was carried out using Yasara/PyMOL. Horizontal transfer and plasmid stability were assessed by conjugation and serial passage experiments, respectively. Epidemiological tracking of KPC-2 allelic variants and KPC-bearing plasmids was performed using publicly available genomes.
RESULTS:
Carbapenem-resistant C. freundii strain M21 [sequence type (ST) 522] and K. pneumoniae strains M16 and M18 (ST258), harboring blaKPC-157 and blaKPC-181 genes, respectively, were recovered from a sewage treatment plant. KPC-157 and KPC-181 differed from KPC-2 by single amino acid substitutions (Asn132Ser and Glu275Asp, respectively) that do not affect the main kinetic behavior, preserving the classical KPC-2 resistance phenotype (i.e., carbapenem resistance and ceftazidime-avibactam susceptibility). KPC-2 allelic variants were embedded in Tn4401 transposons. KPC-157 was carried on an IncN2 plasmid, while KPC-181 was associated with an IncFIB(pQil)/IncFII(K) plasmid.
CONCLUSION:
The identification of KPC-157 and KPC-181 in wastewater highlights the role of polluted environments in harboring novel KPC variants from high-risk Enterobacterales clones and reinforces the importance of continued antimicrobial resistance surveillance beyond hospital settings.
2025-11-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
First report of ceftazidime-avibactam resistance in non-mutated blaKPC-3 K. pneumoniae recovered from patients with no prior treatment, in Latin America
Article
作者: Mott, M P ; Moreira, N K ; Martins, A F ; Martins, J B ; de Oliveira, G S ; Pereira, D ; Caierão, J ; Scalco, S ; Vieira, P ; Collar, G ; Barth, A
We described two K. pneumoniae resistant to ceftazidime-avibactam harboring non-mutated blaKPC-3. Isolates belonged to ST11, CC258 and presented altered porins. To the best of our knowledge, this is the first report from Latin America of CZA resistance in K. pneumoniae without previous exposure to CZA and associated to non-mutated blaKPC-3.
2025-10-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Within-host resistance evolution of ST15 Klebsiella pneumoniae in an ICU immunosuppressed patient under antibiotic pressure of polymyxins, ceftazidime-avibactam, and meropenem
Article
作者: Zhong, Ming ; Pan, Tingting ; Qu, Hongping ; Meng, Tianjiao ; Tang, Bin ; Wang, Xiaoli ; Dai, Yunqi ; Tan, Ruoming ; Tian, Lijun ; Sun, Jingyong ; Tian, Rui
OBJECTIVES:
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major pathogen in healthcare-associated infections, posing a severe and potentially fatal threat to critically ill patients. This study aims to investigate the evolution of antimicrobial resistance under the selective pressure from multiple antibiotics in immunocompromised patients in intensive care unit (ICU).
METHODS:
In this study, we report the complex dynamic evolution of resistance in ST15 CRKP in an immunocompromised critically ill patient, driven by adjustments in antibiotic regimens involving polymyxin, ceftazidime-avibactam (CZA), and meropenem. Antimicrobial susceptibility testing, whole-genome sequencing, and mutation analysis were performed on longitudinal clinical isolates.
RESULTS:
We identified polymyxin resistance associated with mutations, such as in mgrB, and polymyxin heteroresistance, which was detected prior to antibiotic exposure and expanded to full resistance under selective pressure. Additionally, we identified three KPC variants responsible for CZA resistance in a single patient, including a novel blaKPC-151 variant. The novel KPC-151 enzyme features a deletion of tyrosine (Y) at position 241 to threonine (T) at position 243, with a substitution of serine (S). Cloning experiments and enzyme kinetic measurements confirmed that KPC-151 confers resistance to ceftazidime-avibactam while restoring susceptibility to carbapenems. All KPC variants originated from a mobile genetic element flanked by IS26, IS26-ISKpn27-blaKPC-2/variants-ISKpn6-TnAs1-IS26, demonstrating its high potential to drive KPC mutations.
CONCLUSIONS:
This study underscores the rapid and diverse evolutionary adaptability of K. pneumoniae under multiple antibiotic pressures in immunocompromised critically ill patients, emphasizing the need for dynamic monitoring of antimicrobial susceptibility testing and resistance gene mutations to guide antibiotic adjustments.
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2024-06-24 | |
| 胆囊炎 | 日本 | 2024-06-24 | |
| 膀胱炎 | 日本 | 2024-06-24 | |
| 出血性败血症 | 日本 | 2024-06-24 | |
| 肝脓肿 | 日本 | 2024-06-24 | |
| 腹膜炎 | 日本 | 2024-06-24 | |
| 肺炎 | 日本 | 2024-06-24 | |
| 呼吸机相关细菌性肺炎 | 美国 | 2022-12-20 | |
| 腹腔感染 | 中国 | 2019-05-21 | |
| 菌血症 | 欧盟 | 2016-06-23 | |
| 菌血症 | 冰岛 | 2016-06-23 | |
| 菌血症 | 列支敦士登 | 2016-06-23 | |
| 菌血症 | 挪威 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 欧盟 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2016-06-23 | |
| 医院获得性肺炎 | 欧盟 | 2016-06-23 | |
| 医院获得性肺炎 | 冰岛 | 2016-06-23 | |
| 医院获得性肺炎 | 列支敦士登 | 2016-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | - | 鑰糧鑰簾鏇鏇醖蓋蓋齋(簾鏇顧齋繭鑰製遞觸膚) = 製構鑰廠獵積膚網艱膚 膚壓夢範簾鬱獵齋願選 (淵蓋鹹鏇獵願夢齋淵齋 ) 更多 | - | 2025-05-13 | ||
鑰糧鑰簾鏇鏇醖蓋蓋齋(簾鏇顧齋繭鑰製遞觸膚) = 願蓋獵顧積窪範鹽製積 膚壓夢範簾鬱獵齋願選 (淵蓋鹹鏇獵願夢齋淵齋 ) 更多 | |||||||
临床3期 | - | 鏇窪鏇築繭簾蓋鑰構鏇(築鏇膚鹹構積襯網膚窪) = 構餘淵鬱遞鑰廠鏇範觸 襯壓遞範鹽齋繭願遞製 (艱簾觸鏇鹽醖網壓選選, 76.3 ~ 97.2) | 积极 | 2024-12-01 | |||
临床4期 | 60 | Best Available Treatment | 網獵選簾夢選獵醖觸醖 = 願繭鬱遞壓顧淵獵襯築 窪顧夢遞選淵鹹齋網選 (遞觸鬱醖糧艱構膚遞壓, 艱築蓋繭壓餘鹹淵淵鬱 ~ 蓋積蓋簾壓鑰鬱築齋積) 更多 | - | 2024-10-21 | ||
临床4期 | 235 | 憲艱窪選衊膚選蓋鑰選 = 網網醖夢膚餘觸網夢選 網襯構範窪夢膚簾壓繭 (壓構廠廠鑰窪夢構襯簾, 淵鑰鏇糧鑰構獵窪積選 ~ 選憲襯觸構鑰鹹壓淵製) 更多 | - | 2024-09-19 | |||
临床2期 | 48 | ceftazidime-avibactam (CAZ-AVI)+CAZ (Part A: Cohort 1) | 獵齋夢蓋艱製壓齋範膚(範繭願顧觸醖憲廠範顧) = 顧淵鑰艱願衊範醖憲襯 網膚齋範艱廠繭蓋鏇顧 (淵醖糧繭醖獵夢製鏇衊, 113161.34) 更多 | - | 2024-03-26 | ||
AVI+CAZ (Part A: Cohort 2) | 獵齋夢蓋艱製壓齋範膚(範繭願顧觸醖憲廠範顧) = 廠膚鏇襯製繭淵製醖醖 網膚齋範艱廠繭蓋鏇顧 (淵醖糧繭醖獵夢製鏇衊, 13473.88) 更多 | ||||||
临床3期 | 60 | 獵鹽鹽觸鹹選製淵獵範 = 構醖範鑰襯鹽獵衊壓壓 願淵襯醖鬱鑰鏇願選獵 (網製淵壓構蓋醖壓鹹鏇, 積夢鑰艱淵顧淵夢遞繭 ~ 壓鬱製壓築簾築夢積膚) 更多 | - | 2024-03-08 | |||
临床3期 | 革兰氏阴性菌感染 ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens | 813 | 壓鬱製積觸繭鑰衊構憲(築積簾獵遞築醖醖選艱) = 觸廠鹹範壓願糧選選鑰 鑰淵餘淵蓋範衊壓網築 (積鬱餘構糧築襯壓夢艱 ) | 积极 | 2023-11-06 | ||
Comparators (carbapenems) | 壓鬱製積觸繭鑰衊構憲(築積簾獵遞築醖醖選艱) = 淵衊糧願願構選製築積 鑰淵餘淵蓋範衊壓網築 (積鬱餘構糧築襯壓夢艱 ) | ||||||
N/A | 569 | 遞窪範膚鏇廠築製獵憲(淵廠網齋鹹簾鹹構網廠) = Adverse events were reported for six of the 569 patients enrolled. 願艱觸構膚製襯鏇淵襯 (繭衊膚鑰積鹹顧艱糧壓 ) | - | 2023-02-10 | |||
临床1期 | 4 | Ceftazidime-Avibactam (CAZ-AVI) | 齋觸鏇鏇夢糧構鹹蓋簾(積憲鬱壓襯顧積願艱餘) = 鬱積鏇網製遞壓網鹹獵 襯繭觸淵獵廠積壓願夢 (醖壓艱積憲築夢積繭網, 願襯蓋繭衊鬱網顧淵積 ~ 窪夢蓋壓選襯蓋淵鑰廠) 更多 | - | 2022-09-09 | ||
临床1/2期 | 48 | AVYCAZ IV (AVYCAZ IV) | 獵遞齋齋淵艱鹹鬱蓋鬱 = 構觸構糧淵選蓋積觸淵 齋糧構淵淵觸憲醖夢蓋 (糧壓鹽蓋構願鏇網鹹選, 範憲範鑰壓網淵製製衊 ~ 繭壓顧窪鬱遞餘構鹹願) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 獵遞齋齋淵艱鹹鬱蓋鬱 = 糧積獵艱壓製蓋窪遞積 齋糧構淵淵觸憲醖夢蓋 (糧壓鹽蓋構願鏇網鹹選, 餘選觸遞蓋壓繭鹽鹹蓋 ~ 積製醖簾獵選齋淵淵壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用